Suboxone.com - Why Choose SUBOXONE?

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "View PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

You are leaving Suboxone.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals. You are solely responsible for your interactions with such websites.

Links are provided as a public service and for informational purposes only.

You are leaving Suboxone.com and are being redirected to HereToHelpProgram.com, the website that contains the information you requested. HereToHelpProgram.com and Suboxone.com are owned and operated by Reckitt Benckiser Pharmaceuticals Inc.

As always, your information will not be sold or shared with anyone. See our privacy policy for more information.

IMPORTANT INFORMATION:

On December 8, 2006, Federal legislation was passed allowing physicians to treat up to 100 opioid-dependent patients with Suboxone at any given time—a significant increase from the previous limit of 30 patients.

There may be doctors in your area participating in a study to measure opioid dependence treatment outcomes. Patients who meet the eligibility requirements to participate in this study can receive up to $225 in compensation to complete surveys about their treatment.

NOTE: This study is only open to patients not currently under the care of a physician for opioid dependence and are seeking a treatment provider.

Please call 1-866-455-8876 between 9:00 AM to 7:30 PM EST to get more information.

Seeking Information for myself or loved one

Here to Help™ provides support throughout treatment. Whether you're seeking treatment information or you're already in treatment, we can provide resources that can help you make treatment a success.

HereToHelpProgram.com respects your privacy.
Read our Privacy Policy for more information.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

News Room -- Safety Information -- Site Map -- En Español

Ready for Treatment?

See what treatment is like: Watch the video

Find a doctor near you who is certified to treat
opioid dependence

Get FREE support from Here to Help and talk with a live Care Coach
Join today

Could Treatment Help You?

Watch real stories from people who've worked to turn their lives around

Get FREE support from Here to Help and talk with a live Care Coach
Join today

Hear what doctors are saying about Suboxone® and Hear to Help®. Watch Video

Get FREE support from Here to Help and talk with a live Care Coach
Join today

Resource Kit

Learn more about opioid dependence and how you can get help.

Why Choose SUBOXONE?

Opioid dependence isn't just physical. It also affects the way you feel and how you act. That's why successful treatment takes more than medication alone.*

Only SUBOXONE offers built-in support from Here to Help^®, including:

Exclusive access to a live Care Coach, ready to help you stay engaged in your treatment and meet challenges as they arise
Special interactive tools and resources, from real patient stories to fresh ideas for living well
Supportive e-mails to keep you informed and motivated

Medication can only help with the physical part of opioid dependence. It takes more than medication to understand your triggers or learn to cope with high-risk situations. That's why Here to Help not only supports counseling, but helps you connect with a counselor.^†

Take SUBOXONE at home with confidence. While Subutex^® (buprenorphine HCl sublingual tablets) (CIII) is intended to be given under close medical supervision as treatment begins, only SUBOXONE is specially formulated to be taken at home.^‡

Misuse or illegal transfer of Subutex or SUBOXONE could place office-based treatment for opioid dependence at risk. Adding naloxone was an important step in creating an FDA-approved treatment option that could be given in the privacy of a doctor's office and taken in the privacy of your own home.

You can do this... But you don't have to do it alone. SUBOXONE plus Here to Help and counseling means proven support—support that's there to help you every day.*

Fudala PJ, Bridge TP, Herbert S, et al, for the Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.

^†

Data on file, Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA.

^‡

SUBOXONE^® [package insert]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006.

Home -- About SUBOXONE -- Here to Help -- Real Life Stories -- What Is Opioid Dependence? -- Resources -- News Room -- Physician Locator

Glossary -- Contact Us -- Safety Information -- Prescribing Information -- Legal Statement -- Privacy Policy -- Site Map -- En Español

SUBOXONE^®, SUBUTEX^®, and Here to Help^® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.

Important Safety Information

SUBOXONE^® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.

It is extremely dangerous to self-administer non-prescribed benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE.

SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists.

Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine.

Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine.

There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy.

Caution should be exercised when driving cars or operating machinery.

Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately.

The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and sweating (14%, placebo 10%). Please see full Prescribing Information for a complete list.

To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Product Information